Alka, K.; Oyeniyi, J.F.; Mohammad, G.; Zhao, Y.; Marcus, S.; Chinnaiyan, P.
The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines. Cancers 2025, 17, 17.
https://doi.org/10.3390/cancers17010017
AMA Style
Alka K, Oyeniyi JF, Mohammad G, Zhao Y, Marcus S, Chinnaiyan P.
The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines. Cancers. 2025; 17(1):17.
https://doi.org/10.3390/cancers17010017
Chicago/Turabian Style
Alka, Kumari, Jacob F. Oyeniyi, Ghulam Mohammad, Yi Zhao, Stephen Marcus, and Prakash Chinnaiyan.
2025. "The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines" Cancers 17, no. 1: 17.
https://doi.org/10.3390/cancers17010017
APA Style
Alka, K., Oyeniyi, J. F., Mohammad, G., Zhao, Y., Marcus, S., & Chinnaiyan, P.
(2025). The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines. Cancers, 17(1), 17.
https://doi.org/10.3390/cancers17010017